Tag Archives: progression-free survival

New Monoclonal Antibodies Increased Survival in Lung Cancer Patients

Posted on May 30, 2011 by wngai

A new study showed that non-small-cell lung cancer (NSCLC) patients who have high level of Met proteins in their tumor can have their survival increase three-fold by receiving experimental antibody MetMAb in combination with erlotinib (Tarceva).  In the trial, 137 previously-treated … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , | Comments Off on New Monoclonal Antibodies Increased Survival in Lung Cancer Patients

New Personalized Medicine Increases Survival in Melanoma Patients

Posted on April 3, 2011 by wngai

Metastatic melanoma is the deadliest and most aggressive from of skin cancer.  A person with metastatic melanoma typically has a short life expectancy that is measured in months.   The mainstay treatments for metastatic melanoma are dacarbazine (DTIC), interleukin-2 (IL-2) and … Continue reading →

Posted in Cancer, Melanoma | Tagged , , , , , , , , , , , , , , | Comments Off on New Personalized Medicine Increases Survival in Melanoma Patients

Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?

Posted on December 22, 2010 by wngai

A large study of patients with newly diagnosed glioblastoma multiforme suggests that the addition of bevacizumab (Avastin) and irinotecan (Camptosar) to standard chemoradiation can extend survival (progression and overall survival) by 6 months.  Bevacizumab (Avastin) is an inhibitor of vascular … Continue reading →

Posted in Cancer, Glioblastma | Tagged , , , , , , , , , | Comments Off on Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?

Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer

Posted on December 22, 2010 by wngai

Currently, no treatment exists for lung cancer patients with epidermal growth-factor receptor (EGFR) mutation who have failed tyrosine kinase inhibitors, getifinib (Iressa) or erlotinib (Tarceva).  However, an investigational drug, afatinib (BIBW 2992), was recently found to increase progression-free survival and … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , , , , | Comments Off on Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer

Europe Approved Sutent for Rare Pancreatic Cancer

Posted on December 22, 2010 by wngai

The European Commission has recently approved Sutent (sunitinib) as a medicine for treating patients with pancreatic neuroendocrine tumors (NET).   The drug is now indicated to treat unresectable metastatic, well-differentiated pancreatic NET in adults with disease progression.  The approval was based … Continue reading →

Posted in Cancer, Pancreatic Cancer | Tagged , , , , , | Comments Off on Europe Approved Sutent for Rare Pancreatic Cancer